Product Description: PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively[1].
Applications: Cancer-Kinase/protease
Formula: C21H20F3N7O3S
Citations: Anticancer Drugs. 2023 Jul 14./Breast Cancer Res. 2024 Mar 19;26(1):48./Cancer Res. 2013 May 1;73(9):2873-83./Carbohydr Polym. 2024 Feb 15, 326, 121637./Cell Death Dis. 2022 Sep 10;13(9):783./Cell Death Dis. 2023 Feb 24;14(2):157./Cell Discov. 2022 Sep 6;8(1):84./Cell Rep. 2023 Oct 5;42(10):113213./Clin Cancer Res. 2019 Jul 15;25(14):4552-4566./Environ Toxicol Pharmacol. 2023 Oct 20:104301./Eur J Cell Biol. 2024 May 28;103(2):151427./Harvard Medical School LINCS LIBRARY/Int J Cancer. 2015 Oct 1;137(7):1549-59./J Nat Med. 2020 Sep;74(4):732-740./Life Sci. 2021 Jan 25;119112./Practical Oncology Journal. 2015, 29(5): 444-449./Research Square Preprint. 2021 Dec./Research Square Preprint. 2023 May 23./Sci Rep. 2018 May 8;8(1):7228. /Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
References: [1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68(6), 1935-1944./[2]Crompton BD, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1;73(9):2873-83./[3]Bagi CM, et al. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112(10):2313-21.
CAS Number: 717907-75-0
Molecular Weight: 507.49
Compound Purity: 99.68
Research Area: Cancer
Solubility: DMSO : 66.67 mg/mL (ultrasonic)
Target: FAK;Pyk2
Deutsch
English
